Prurigo nodularis
MONDO:0026045Prurigonodularis (PN) is a skin disease in which hard crusty lumps are formed on the skin that itches intensely. Repetitive rubbing, scratching, and touching results in more lesions in the skin. The itching is so intense that people scratch themselves to the point of bleeding or pain. The lumps formed in the skin are hard, and have about a half inch across, with a dry and rough top that is often scratched open. They tend to be located in the areas most easily reached and are worse on the outer sides: arms, shoulders and legs. The trunk, face and even palms can also be affected. The exact cause is unknown but some factors triggering PN include liver and kidneys problems, nervous and mental conditions and other skin diseases. Prurigo nodulares, in some cases, can be seen in other diseases such as lymphoma, chronic autoimmune cholestatic hepatitis, HIV infection, severe anemia,or a chronic kidney disease-related itching known as uremic pruritus. Treatment is very difficult, and may include corticoids, antihistaminic and other medication such as thalidomide and similar (Lenalidomide). In some cases, cryotherapy, photochemotherapy and habit reversal therapy for the itch-scratch cycle has improved the symptoms. PN can last for many years, and the itching is so intense that may affect all the everyday activities.
29 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsBroader categories
-
New pill aims to stop the itch of prurigo nodularis
Disease control OngoingThis phase 3 trial tests an oral drug called povorcitinib in 346 adults with prurigo nodularis, a condition causing intense itching and bumpy skin lesions. Participants receive either the drug or a placebo for 24 weeks. The study measures whether the drug reduces itch severity an…
Phase: PHASE3 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Real-World dupilumab study aims to ease chronic itch
Disease control OngoingThis study follows 100 adults with prurigo nodularis who are already prescribed dupilumab (Dupixent) by their doctor. Researchers will track why patients start or stop the drug, how well it controls itching and skin bumps, and any hospital visits. The goal is to see how dupilumab…
Sponsor: Sanofi • Aim: Disease control
Last updated Jun 26, 2026 18:00 UTC
-
New drug could soothe uncontrollable itch in rare skin condition
Symptom relief OngoingThis phase 3 trial tests an oral drug called povorcitinib in 349 adults with prurigo nodularis, a condition causing intense itching and hard skin bumps. Participants receive either the drug or a placebo for 24 weeks. The goal is to see if the drug reduces itch and clears skin les…
Phase: PHASE3 • Sponsor: Incyte Corporation • Aim: Symptom relief
Last updated Jun 27, 2026 12:39 UTC
-
New drug aims to calm relentless itch of prurigo nodularis
Symptom relief OngoingThis phase 3 study tests rocatinlimab, an injectable drug, against a placebo in 469 adults with prurigo nodularis—a condition causing intense itching and hard bumps on the skin. Participants had not gotten enough relief from topical treatments. The main goal is to see if the drug…
Phase: PHASE3 • Sponsor: Amgen • Aim: Symptom relief
Last updated Jun 27, 2026 12:29 UTC
-
New shot aims to stop the itch of prurigo nodularis
Symptom relief OngoingThis phase 2 trial tests a drug called barzolvolimab in 140 adults with prurigo nodularis, a skin condition causing intense itching and hard bumps. Participants receive either the drug or a placebo as a shot under the skin. The main goal is to see if the drug reduces itch severit…
Phase: PHASE2 • Sponsor: Celldex Therapeutics • Aim: Symptom relief
Last updated Jun 27, 2026 09:00 UTC
-
New drug shows promise for chronic itch in Long-Term trial
Symptom relief OngoingThis study looks at the long-term safety of nemolizumab in 500 adults with prurigo nodularis, a condition causing severe itching and skin bumps. Participants must have taken nemolizumab in a previous study. The main goal is to track side effects over time, while also checking if …
Phase: PHASE3 • Sponsor: Galderma R&D • Aim: Symptom relief
Last updated Jun 27, 2026 07:57 UTC
-
AI vs. skin doctors: who diagnoses better?
Knowledge-focused ENROLLING_BY_INVITATIONThis study looks at whether artificial intelligence (AI) can match a dermatologist's diagnosis when a general practitioner sends in photos and questions about a patient's skin condition. Researchers will compare the AI's diagnosis to the dermatologist's for about 1000 adults. The…
Sponsor: Centre Hospitalier Universitaire de Nice • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:11 UTC